The global secondary myelofibrosis therapeutics market, valued at USD 1.4 million in 2022, is set to experience notable growth over the coming decade, projected to expand at a CAGR of 6.3% from 2023 to 2033 and reach a valuation of USD 2.74 million by the end of the forecast period. Key drivers of this growth …